|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0011847,
umls-concept:C0011860,
umls-concept:C0023981,
umls-concept:C0041700,
umls-concept:C0085580,
umls-concept:C0332307,
umls-concept:C0342257,
umls-concept:C0851285,
umls-concept:C1273870,
umls-concept:C2603343
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
1999-7-27
|
|
pubmed:abstractText |
Patients with type 2 diabetes mellitus often develop micro- and macrovascular complications. In 25% of them, complications are already present at the time of diagnosis. The principal objective of the United Kingdom prospective diabetes study was to determine if good blood glucose control and adequate treatment of hypertension in patients with type 2 diabetes mellitus can prevent development of diabetes-related complications. The question was also studied if they way in which this blood glucose control was achieved and the way of treating the blood pressure affected the prognosis. Blood glucose control was found to reduce the incidence of--especially--microvascular complications. Oral hypoglycaemic agents and insulin both play an important part in achieving good control. Treatment with metformin reduced mortality due to cardiovascular disease in obese patients. Strict control of the blood pressure reduced development of micro- and macrovascular complications; the mortality from diabetes-related disorders and the numbers of patients suffering a stroke or heart failure. Non of the antihypertensive drugs used (an ACE inhibitor and a beta-blocking agent) offered any advantages over the other.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
dut
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0028-2162
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
5
|
|
pubmed:volume |
143
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1197-201
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10389533-Adrenergic beta-Antagonists,
pubmed-meshheading:10389533-Adult,
pubmed-meshheading:10389533-Aged,
pubmed-meshheading:10389533-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:10389533-Antihypertensive Agents,
pubmed-meshheading:10389533-Cerebral Infarction,
pubmed-meshheading:10389533-Coronary Disease,
pubmed-meshheading:10389533-Diabetes Mellitus, Type 2,
pubmed-meshheading:10389533-Diabetic Angiopathies,
pubmed-meshheading:10389533-Female,
pubmed-meshheading:10389533-Great Britain,
pubmed-meshheading:10389533-Humans,
pubmed-meshheading:10389533-Hyperglycemia,
pubmed-meshheading:10389533-Hypertension,
pubmed-meshheading:10389533-Hypoglycemic Agents,
pubmed-meshheading:10389533-Insulin,
pubmed-meshheading:10389533-Male,
pubmed-meshheading:10389533-Metformin,
pubmed-meshheading:10389533-Middle Aged,
pubmed-meshheading:10389533-Peripheral Vascular Diseases,
pubmed-meshheading:10389533-Prospective Studies,
pubmed-meshheading:10389533-Survival Rate
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
[Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications].
|
|
pubmed:affiliation |
Afd. Endocrinologie, Academisch Ziekenhuis Maastricht. bwo@sint.azm.nl
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract,
Review
|
